Arndt Justus Georg Schottelius
Director/Board Member at GUBRA A/S
Net worth: 407 685 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John McCafferty | M | 66 |
Maxion Therapeutics Ltd.
 Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 years |
| Harry Welten | M | 59 | 4 years | |
| Aneesh Karatt-Vellatt | M | 37 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 years |
| Niels Vrang | M | 56 | 16 years | |
| Alexander Thomas Martensen-Larsen | M | 48 | 2 years | |
| Uta Kemmerich-Keil | F | 58 | 3 years | |
| Henriette Draebye Rosenquist | F | 55 | 2 years | |
| Jacob Jelsing | M | 50 | 16 years | |
| Kristian Borbos | M | 46 | 2 years | |
| Constanze Ulmer-Eilfort | M | 62 | 1 years | |
| Kristoffer Rigbolt | M | - | 2 years | |
| Trine Nygaard Hamann | F | - | 4 years | |
| Alexander Fudukidis | M | - | 4 years | |
| Lucy Edwardes Jones | F | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
| Thomas Weaver | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | - |
| Tim Funnell | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 2 years |
| Sohaib Mir | M | 42 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
| Annalisa Jenkins | M | 58 | 4 years | |
| Eva-Lotta Allan | F | 65 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 years |
| Mads Buhl Axelsen | M | 66 | 2 years | |
| Henrik Blou | M | 45 | 8 years | |
| Helle Kirstein Erichsen | F | - | 7 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Adolf Hoess | M | 62 | 14 years | |
| Ferdinand Verdonck | M | 81 | 7 years | |
| Berndt A. E. Modig | M | 65 | 6 years | |
| Angus Smith | M | 41 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Denmark | 10 | 38.46% |
| Germany | 9 | 34.62% |
| United Kingdom | 7 | 26.92% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Arndt Justus Georg Schottelius
- Personal Network
